Jupiter Neurosciences Explores Strategic Options
MT newswire2026/10/06 15:5511:55 AM EDT, 10/06/2026 (MT Newswires) -- Jupiter Neurosciences (JUNS) said Tuesday it has started a process to evaluate strategic options, including sale or licensing, strategic partnerships, and business combinations. The firm said it has engaged Tungsten Advisors as its advisor in the plan to maximize shareholder value. It added that there can be no assurance that the process will result in any transaction. Jupiter also reported that the first patient has been dosed in its phase 2a trial of Jotrol in patients with Parkinson's disease, with about 30 patients expected to be enrolled in the study. Price: 2.39, Change: -0.03, Percent Change: -1.24
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
